This phase II study evaluated docetaxel/oxaliplatin (TE), docetaxel/oxaliplatin/5–fluorouracil (TEF) and docetaxel/oxaliplatin/capecitabine (TEX) in patients with advanced gastric cancer. The results suggest that TEF is worthy of evaluation as an arm in a phase III trial or as a backbone regimen for new targeted agents in advanced gastric cancer.

READ FULL ARTICLE Curated publisher From Mdlinx